Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,065,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the sale, the chief operating officer now directly owns 896,869 shares of the company’s stock, valued at $9,551,654.85. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $10.38 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06. The firm has a fifty day moving average price of $11.12 and a two-hundred day moving average price of $11.59. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of -69.20 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

ROIV has been the subject of several analyst reports. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $18.08.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently modified their holdings of ROIV. FMR LLC raised its stake in Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock valued at $583,238,000 after purchasing an additional 156,527 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after buying an additional 2,404,232 shares during the last quarter. State Street Corp lifted its stake in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares during the period. Patient Square Capital LP grew its position in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after buying an additional 251,535 shares in the last quarter. Finally, Two Seas Capital LP increased its stake in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock valued at $120,285,000 after acquiring an additional 442,914 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.